https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27892 Wed 11 Apr 2018 16:44:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27041 Wed 11 Apr 2018 16:32:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30223 In vitro antivenom efficacy studies were compared to rodent lethality studies to test two Indian snake antivenoms (VINS and BHARAT) against four Sri Lankan snakes. In vitro efficacy was tested at venom concentrations consistent with human envenoming. Efficacy was compared statistically for one batch from each manufacturer where multiple vials were available. In binding studies EC₅₀ for all VINS antivenoms were less than BHARAT for D. russelii [553 μg/mL vs. 1371 μg/mL;p=0.016), but were greater for VINS antivenoms compared to BHARAT for N. naja [336 μg/mL vs. 70 μg/mL;p<0.0001]. EC₅₀ of both antivenoms was only slighty different for E. carinatus and B. caeruleus. For procoagulant activity neutralisation, the EC₅₀ was lower for VINS compared to BHARAT - 60 µg/mL vs. 176 µg/mL (p<0.0001) for Russell's viper and 357 µg/mL vs. 6906µg/mL (p<0.0001) for Saw-scaled viper. Only VINS antivenom neutralized in vitro neurotoxicity of krait venom. Both antivenoms partially neutralized cobra and didn't neutralize Russell's viper neurotoxicity. Lethality studies found no statistically significant difference in ED₅₀ values between VINS and BHARAT antivenoms. VINS antivenoms appeared superior to BHARAT at concentrations equivalent to administering 10 vials antivenom, based on binding and neutralisation studies. Lethality studies were inconsistent suggesting rodent death may not measure relevant efficacy outcomes in humans.]]> Wed 11 Apr 2018 16:22:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52170 Wed 04 Oct 2023 10:55:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52579 Tue 17 Oct 2023 15:49:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52539 Tue 17 Oct 2023 10:12:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44240 Tue 11 Oct 2022 11:55:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50562 Tue 01 Aug 2023 10:19:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7732 Thu 06 Dec 2018 12:06:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29594 Thu 03 Feb 2022 12:21:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48125 Thu 02 Mar 2023 15:06:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20621 Sat 24 Mar 2018 07:55:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44908 Mon 24 Oct 2022 16:17:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44175 Mon 10 Oct 2022 10:13:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39977 Fri 22 Jul 2022 11:56:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38954 90% passing 2%/2mm/10% threshold) and ≤ 1 mm positional accuracy at target-cord interface was required. Results: 19 centres were credentialed; 11 had on-site measurement. Delivery devices included linear accelerator, TomoTherapy and CyberKnife systems. Five centres did not achieve 90% gamma passing rate. Of these, three were out of tolerance (OOT) in low (<5Gy) dose regions and > 80% passing rate and deemed acceptable. Two were OOT over the full dose range: one elected not to remeasure; the other also had positional discrepancy greater than 1 mm and repeat measurement with a new plan was in tolerance. The original OOT was attributed to inappropriate MLC constraints. All centres delivered planned target-cord dose gradient within 1 mm. Conclusion: Credentialing measurements for vertebral SABR in a multi-centre trial showed although the majority of centres delivered accurate vertebral SABR, there is high value in independent audit measurements. One centre with inappropriate MLC settings was detected, which may have resulted in delivery of clinically unacceptable vertebral SABR plans.]]> Fri 11 Mar 2022 15:47:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]>